has function has role vaccinated in route immunizes against disease immunizes recipient melanoma Homo sapiens melanoma vaccine subcutaneous route therapeutic vaccine function peptide vaccine vaccine in clinical trial role peptide vaccine role therapeutic cancer vaccine multi-epitope melanoma peptide vaccine cancer vaccine 4102 6318 Gene name: MAGE-A3 6490 Gene name: tyrosinase Jie Zheng NCT: https://clinicaltrials.gov/study/NCT00085189 3106 Hayleigh Kahn VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6318 3105 Gene name: HLA-B Gene name: HLA-A NCI: https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C38695 7299 Gene name: gp100 A cancer vaccine consisting of a combination of peptides derived form several melanoma epitopes. Vaccination with multi-epitope melanoma peptide vaccine stimulates the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing the corresponding antigens, resulting in tumor cell lysis. This vaccine may stimulate a broader CTL response compared to single-antigen vaccines. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells in patients with stage IIC-IV melanoma. This vaccine is a tyrosinase/gp100/MAGE-3 class I peptide vaccine combined with Montanide ISA 51 or ISA 51 VG with CpG adjuvant 7909 in human leukocyte antigen (HLA) class I A1, A3 or A11 and B44 matched patients with surgically resected stages IIC, III and IV melanoma.